Risks

Net debt to EBITDA is extremely elevated versus listed peers, so refinancing or rate pressure could constrain earnings and valuation more than for lower-levered competitors.

Interest coverage is effectively absent in the supplied metrics, which leaves CHYM more exposed than peers if operating cash flow weakens or funding costs rise.

Days sales outstanding of 44.4 suggests working-capital collection risk, so cash realization may lag peers with tighter receivables management and stronger liquidity conversion.

The cash conversion cycle is only marginally positive, which limits buffer versus peers if demand softens or inventory and receivable timing becomes less favorable.

Debt-to-equity is low, but the leverage profile still appears debt-heavy relative to equity, so balance-sheet flexibility may remain weaker than better-capitalized peers.

Opportunities

The very high current and quick ratios indicate substantial near-term liquidity, which could support CHYM better than peers during demand volatility or funding stress.

A near-zero cash conversion cycle suggests efficient operating cash timing, giving CHYM a working-capital advantage versus peers with slower cash release.

Low debt-to-equity relative to the reported liquidity profile may provide optionality for growth funding, potentially improving resilience versus more stretched competitors.

If receivables remain collectible at current levels, CHYM can preserve liquidity longer than peers with weaker cash conversion, supporting steadier operating continuity.

Overall Score

CHYM’s strong liquidity and efficient cash conversion offset, but do not fully neutralize, the materially elevated leverage and weak coverage profile versus peers.